Literature DB >> 21642542

Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.

Zuqiang Liu1, Louis D Falo, Zhaoyang You.   

Abstract

Although high mobility group box 1 (HMGB1) in tumor cells is involved in many aspects of tumor progression, its role in tumor immune suppression remains elusive. Host cell-derived IL-10 suppressed a naturally acquired CD8 T cell-dependent antitumor response. The suppressive activity of tumor-associated Foxp3(+)CD4(+)CD25(+) regulatory T cells (Treg) was IL-10 dependent. Neutralizing HMGB1 impaired tumor cell-promoted IL-10 production by Treg. Short hairpin RNA-mediated knockdown of HMGB1 (HMGB1 KD) in tumor cells did not affect tumor cell growth but uncovered naturally acquired long-lasting tumor-specific IFN-γ- or TNF-α-producing CD8 T cell responses and attenuated their ability to induce Treg, leading to naturally acquired CD8 T cell- or IFN-γ-dependent tumor rejection. The data suggest that tumor cell-derived HMGB1 may suppress naturally acquired CD8 T cell-dependent antitumor immunity via enhancing Treg to produce IL-10, which is necessary for Treg-mediated immune suppression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642542      PMCID: PMC3119781          DOI: 10.4049/jimmunol.1003378

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 2.  Interleukin-10 and the immune response against cancer: a counterpoint.

Authors:  Simone Mocellin; Francesco M Marincola; Howard A Young
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

3.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.

Authors:  Purevdorj B Olkhanud; Bazarragchaa Damdinsuren; Monica Bodogai; Ronald E Gress; Ranjan Sen; Katarzyna Wejksza; Enkhzol Malchinkhuu; Robert P Wersto; Arya Biragyn
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

4.  Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.

Authors:  Jin H Kim; Nilanjana Majumder; Honghui Lin; Janet Chen; Louis D Falo; Zhaoyang You
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

Review 5.  The cytokine activity of HMGB1.

Authors:  Huan Yang; Haichao Wang; Christopher J Czura; Kevin J Tracey
Journal:  J Leukoc Biol       Date:  2005-02-25       Impact factor: 4.962

Review 6.  HMGB1: guiding immunity from within.

Authors:  Ingrid E Dumitriu; Paramita Baruah; Angelo A Manfredi; Marco E Bianchi; Patrizia Rovere-Querini
Journal:  Trends Immunol       Date:  2005-07       Impact factor: 16.687

7.  T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.

Authors:  S Sharma; M Stolina; Y Lin; B Gardner; P W Miller; M Kronenberg; S M Dubinett
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

9.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

10.  Altered immune responses in interleukin 10 transgenic mice.

Authors:  A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

View more
  39 in total

1.  Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Authors:  Shenghe Tian; Zuqiang Liu; Cara Donahue; Louis D Falo; Zhaoyang You
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 2.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases.

Authors:  Tao Gong; Lei Liu; Wei Jiang; Rongbin Zhou
Journal:  Nat Rev Immunol       Date:  2019-09-26       Impact factor: 53.106

3.  Nuclear factor of activated T cells regulates neutrophil recruitment, systemic inflammation, and T-cell dysfunction in abdominal sepsis.

Authors:  Su Zhang; Lingtao Luo; Yongzhi Wang; Maria F Gomez; Henrik Thorlacius
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

Review 4.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

Review 5.  DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.

Authors:  Jin Huang; Yangchun Xie; Xiaofang Sun; Herbert J Zeh; Rui Kang; Michael T Lotze; Daolin Tang
Journal:  Ageing Res Rev       Date:  2014-10-30       Impact factor: 10.895

6.  Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells.

Authors:  Jessica E Thaxton; Bei Liu; Pan Zheng; Yang Liu; Zihai Li
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

7.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro.

Authors:  Samantha A Chalmers; Alec S Eidelman; Jason C Ewer; Jacob M Ricca; Antonio Serrano; Kyle C Tucker; Caroline M Vail; Robert A Kurt
Journal:  Cell Immunol       Date:  2013-05-14       Impact factor: 4.868

Review 9.  Novel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis: A systemic review.

Authors:  Li-Feng Huang; Yong-Ming Yao; Zhi-Yong Sheng
Journal:  World J Emerg Med       Date:  2012

Review 10.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.